- Open Access
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Diagnostic Pathology volume 11, Article number: 95 (2016)
A high-quality programmed cell-death ligand 1 (PD-L1) diagnostic assay may help predict which patients are more likely to respond to anti-programmed cell death-1 (PD-1)/PD-L1 antibody-based cancer therapy. Here we describe a PD-L1 immunohistochemical (IHC) staining protocol developed by Ventana Medical Systems Inc. and key analytical parameters of its use in formalin-fixed, paraffin-embedded (FFPE) samples of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
An anti-human PD-L1 rabbit monoclonal antibody (SP263) was optimized for use with the VENTANA OptiView DAB IHC Detection Kit on the automated VENTANA BenchMark ULTRA platform. The VENTANA PD-L1 (SP263) Assay was validated for use with FFPE NSCLC and HNSCC tissue samples in a series of studies addressing sensitivity, specificity, robustness, and precision. Samples from a subset of 181 patients from a Phase 1/2 study of durvalumab (NCT01693562) were analyzed to determine the optimal PD-L1 staining cut-off for enriching the probability of responses to treatment. The scoring algorithm was defined using statistical analysis of clinical response data from this clinical trial and PD-L1 staining parameters in HNSCC and NSCLC tissue. Inter-reader agreement was established by three pathologists who evaluated 81 NSCLC and 100 HNSCC samples across the range of PD-L1 expression levels.
The VENTANA PD-L1 (SP263) Assay met all pre-defined acceptance criteria. For both cancer types, a cut-off of 25 % of tumor cells with PD-L1 membrane staining of any intensity best discriminated responders from nonresponders. Samples with staining above this value were deemed to have high PD-L1 expression, and those with staining below it were deemed to have low or no PD-L1 expression. Inter-reader agreement on PD-L1 status was 97 and 92 % for NSCLC and HNSCC, respectively.
These results highlight the robustness and reproducibility of the VENTANA PD-L1 (SP263) Assay and support its suitability for use in the evaluation of NSCLC and HNSCC FFPE tumor samples using the devised ≥25 % tumor cell staining cut-off in a clinical setting. The clinical utility of the PD-L1 diagnostic assay as a predictive biomarker will be further validated in ongoing durvalumab studies.
This article provides the full results of two abstracts that have previously been presented and published [1, 2].
Patients with recurrent and metastatic non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) have considerable unmet medical needs and require improved treatments with the potential to provide prolonged survival and reduced exposure to toxic chemotherapies [3–5].
It has long been recognized that the immune system is capable of recognizing cancer as foreign and developing a specific immune response. A number of stimulatory and opposing inhibitory proteins have been shown to regulate the quality and magnitude of the antitumor response [6–9]. For example, tumors can evade detection by the immune system by exploiting one or more of the inhibitory (checkpoint) pathways that suppress antitumor T-cell responses . The therapeutic blockade of these checkpoint molecules is actively being explored across different cancers [6, 7]. One of the most promising approaches is antibody blockade of the programmed cell death-1 (PD-1)/ programmed cell death ligand-1 (PD-L1) pathway [6, 7]. The anti-PD-1 agents nivolumab and pembrolizumab have demonstrated clinical activity across several tumor types and are now approved for various indications worldwide [10–13]. While dramatic responses have been seen in a number of patients treated with anti-PD-1 and anti-PD-L1 antibodies, responses have typically represented only a fraction of treated patients. This has led to a further search for biomarkers predictive of response. Chief among these is the demonstration of PD-L1 in tumor tissues using immunohistochemistry (IHC). Two different IHC assays have so far been approved by the Food and Drug Administration (FDA) for use as diagnostic tests in advanced NSCLC; a complementary diagnostic for nivolumab  and a companion diagnostic for pembrolizumab .
PD-L1 (B7-H1, CD274) is part of a complex system of receptors and ligands that are involved in regulating T-cell activation. Its main function is to regulate the balance between T-cell activation and tolerance through interaction with its two receptors, PD-1 (CD279) and CD80 (B7-1). In normal tissue, PD-L1 has been reported to be expressed on a subset of T cells, B cells, dendritic cells, macrophages, mesenchymal stem cells, and bone marrow-derived mast cells, as well as various non-hematopoietic cells [16, 17]. PD-L1 is expressed in a limited set of normal epithelial cells, such as placental trophoblast cells and crypt epithelium of the tonsil . Its expression in these locations is thought to provide protection from cell-mediated attack. Importantly, and in a similar fashion, PD-L1 is also expressed in a broad range of carcinomas and other cancers [19–22] including NSCLC and HNSCC [9, 16]. In the tumor microenvironment, PD-L1 expressed on tumor cells binds to PD-1 on activated T cells reaching the tumor. This delivers an inhibitory signal to those T cells, preventing them from killing target tumor cells, and protecting the tumor from immune elimination .
PD-L1 biology is further complicated in additional ways. For example, full-length PD-L1 is composed of an extracellular domain that contains the PD-1 binding domain, a shorter intracellular domain, and a short transmembrane region. A number of antibodies to the extracellular and intracellular domains have been generated and several of those appear useful as IHC reagents [22–24]. It is also the case that splice variants of PD-L1 have been identified [25, 26] and individual isoforms may localize to the cytoplasm or membrane of cells in vitro. It should be noted, however, that particular forms of the PD-L1 protein may be recognized by some but not all of the other available antibodies. Cytoplasmic or membrane immunolabeling of neoplastic cells and macrophages have also been shown in tumor tissues [19, 27]. PD-L1 localization to the cell membrane is likely required for interaction with PD-1. In addition, PD-L1 demonstrates a range of apparent expression levels in cells, whether cytoplasmic or membranous. Tumor cells or immune cells with variable intensities of PD-L1 expression could therefore suppress PD-1-expressing T lymphocytes to different degrees, although this has not yet been proven. In addition to the biological heterogeneity of PD-L1 expression (notably intra- and inter-tumoral and temporal variations), [28, 29] there is also technical variability due to a number of different assays (developed for diagnostic or research use) being used to label PD-L1 in tumor tissue. These have variable target specificity and selectivity (being raised to different epitopes on the PD-L1 molecule), and use different methods for antibody detection and approaches to determining PD-L1 expression (scoring systems and staining cut-offs) .
Not surprisingly then, given the various complexities noted, substantial discordance is seen among published studies relying on PD-L1 IHC [22–24]. Nonetheless, the ability of a PD-L1 IHC method to account for those key aspects of PD-L1 biology and tissue expression relevant to therapy with either PD-1 or PD-L1 antibodies is expected to substantially contribute the overall usefulness of the assay. In that context, for example, an assay that demonstrates distinct cell membrane staining and a dynamic range of PD-L1 expression is highly desired. In addition, the ability to optimally label PD-L1 on neoplastic cells as well as immune cells is important, as is the ability to perform across the range of tissue specimens upon which the assay is expected to be applied. These qualities are especially needed to increase the ability to accurately identify patients who may respond to immunotherapies targeting PD-L1 or PD-1. At the same time, they contribute to a more comprehensive and potentially accurate assessment of PD-L1 that reflects the complexities of its expression in a range of tumor types and that may be required to clarify aspects of its immunosuppressive role in cancer that are not yet fully understood.
Durvalumab (MEDI4736) is a selective, high-affinity human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 but does not bind to programmed cell death ligand-2 (PD-L2) . PD-L2 plays a role in controlling inflammation in normal lung tissue (with expression in lung macrophages and antigen-presenting cells)  and this may help to avoid PD-L2-mediated immune-related toxicities, which have been observed in animal models [32, 33]. In an ongoing Phase 1/2 study of patients with advanced solid tumors, durvalumab monotherapy has demonstrated a manageable tolerability profile and encouraging antitumor activity across multiple tumor types, including NSCLC and HNSCC [34, 35].
Most NSCLC tumors do not express PD-L1 at high levels, although reported levels vary; [20, 36, 37] only ~20 % of NSCLC tumors were reported to show PD-L1 expression in 5 % or more of tumor cells obtained with three different IHC assays (using different PD-L1 antibody clones; E1L3N, 22C3, and 5H1) [20, 38, 39]. In HNSCC, tissue PD-L1 immunostaining increases vs. normal controls  with variable levels of PD-L1 expression [18, 35, 40]. The absence of detectable PD-L1 in some tumors may account for poor responses to anti-PD-1/PD-L1 therapy. A sensitivity analysis of the clinical activity of nivolumab, pembrolizumab, and the anti-PD-L1 agent atezolizumab in NSCLC [41–48] demonstrated that overall response rates were significantly lower in patients with PD-L1 low tumors (1–5 % tumor cells stained using various PD-L1 assays) than in patients with PD-L1 high tumors . Evidence from some individual clinical studies of the anti-PD-1/PD-L1 agents nivolumab, durvalumab, pembrolizumab, atezolizumab, and avelumab also suggest that patients with PD-L1 high tumors can experience improved treatment benefits vs. those with PD-L1 low tumors [34, 43, 47, 49, 50].
The development and application of diagnostic tests in clinical practice to identify patients most likely to benefit from anti-PD-1/PD-L1 therapy could improve patient outcomes and decrease healthcare costs, while directing patients that are less likely to respond towards other alternative treatment options. Research into the relative performance of different PD-L1 assays and their reliability for detecting PD-L1 is ongoing . These diagnostic tests, which are designed to aid treatment decisions with specific anti-PD-1 therapies [23, 29, 52], are likely to be among the key drivers for the future of personalized health care in oncology .
In this paper, we describe the development and validation of the VENTANA PD-L1 (SP263) Assay (PD-L1 [SP263]) (Ventana Medical Systems Inc., Tucson, AZ, USA), which has been designed for the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) NSCLC and HNSCC tumor samples. In addition, we describe the identification and validation of scoring criteria (defined with tissues from a durvalumab clinical trial) that can be used to classify samples as PD-L1 high expression or PD-L1 low/no expression in NSCLC and HNSCC tissue.
PD-L1 (SP263) assay
The PD-L1 (SP263) assay uses an anti-human PD-L1 rabbit monoclonal antibody (SP263) directed against the cytoplasmic region of human PD-L1. This peptide was synthesized and conjugated to the carrier protein keyhole limpet hemocyanin. New Zealand White rabbits were immunized with keyhole limpet hemocyanin conjugated peptide emulsified with complete Freund’s adjuvant followed by a series of booster doses of immunogen emulsified with incomplete Freund’s adjuvant. The rabbit that generated IHC-positive polyclonal antibody was then selected for monoclonal antibody development using Spring Bioscience’s proprietary technology.
Briefly, antibody-expressing cells were isolated and screened by enzyme-linked immunoabsorbent assay for reactivity to the immunogen and by IHC on control tissue blocks. Complementary DNA coding for antibody heavy chains and light chains was isolated from IHC-positive clones. Monoclonal antibodies were produced by co-transfection of heavy- and light-chain complementary DNA and tested again by IHC. The clone producing antibodies with the best specificity was selected. A larger transfected production lot was produced and the monoclonal antibody was purified through a Protein A column.
The antibody was designed to be used in conjunction with the VENTANA OptiView diaminobenzidine tetrahydrochloride (DAB) IHC Detection Kit (P/N 760-700) and the staining protocol for the assay is provided in Table 1. This protocol represents the selectable options within the detection kit procedure. The OptiView DAB IHC Detection Kit is an indirect, biotin-free system for detecting mouse IgG, mouse IgM, and rabbit primary antibodies used to detect target antigens in FFPE tissue, The 3-hydroxy-2-quinoxalinecarbamide (hydroxyquinoxaline) universal linker conjugated with hydroxyquinoxaline haptens binds to the primary antibody and is recognized by the horse radish peroxidase multimer. The remaining components in the detection kit function to create a brown 3,3’-DAB precipitate on the tissue section at the site of PD-L1 antigen.
Normal-term placenta can be used as a positive and negative tissue control for the assay. Tissue controls were used to monitor the correct performance of processed tissues, test reagents, and instruments. One placenta control was included on each staining run.
Cell line analysis of PD-L1 expression
The SP263 antibody was tested by immunocytochemistry on the following cell lines: Calu-3, KARPASS 299, H820, H1975, MDA-MB231, T-47D, LOX, ACHN, MCF-7, and HCT-116. In addition, HEK293 cell lines transfected to express varying levels of PD-L1 were prepared to test PD-L1 expression across the dynamic range and were also transfected to express PD-L2 to demonstrate antibody specificity.
Flow cytometry analysis
Tumor cell lines (LOX, MCF-7, MDA-MB231, HCT116, and ACHN) were evaluated for surface PD-L1 expression and the number of receptors per cell was estimated using flow cytometry. Briefly, tumor cell suspensions were incubated with 100 μl of anti-human PD-L1 antibody (R&D systems, catalog MAB1561) diluted in flow cytometry analysis (FACS) buffer (phosphate-buffered saline plus 2 % heat inactivated fetal bovine serum) for 45 min at 4 °C. After primary monoclonal antibody incubation, cells were washed with cold FACS buffer and resuspended in 100 μl QIFI Kit FITC secondary antibody diluted 1:50 with FACS buffer (Dako QIFI Kit, catalog #K0078, lot 00088291). Secondary detection antibody incubation was conducted for 45 min at 4 °C, protected from light. After secondary incubation, cells were washed once with cold FACS buffer and resuspended in FACS buffer for flow cytometric analysis performed on a BD LSR II Flow Cytometer (BD Biosciences, Mountain View, CA, USA). Using the setup provided in the QIFI kit, a standard curve was plotted using the mean fluorescent intensity values and calculated using GraphPad Prism 6 software. The x values were determined, which correlated to the number of receptors per cell.
Western blot analyses of cell lysates
Western blot studies were conducted by SDS-PAGE. Cell lysates were prepared from four different cell lines that demonstrated varying IHC protein expression (H820, MDA-MB231, H1975, and Calu-3 cell lines). A recombinant human PD-L1 protein served as a positive control and a recombinant BCL-2 protein served as a negative control for the study. An anti-actin antibody (8H10D10) (Cell Signaling Technologies, Danvers, MA, USA) was used to detect a ~42 kD protein actin. This constitutively expressed reference protein ensured equivalent loading of samples onto the gel.
Staining of commercially available normal and tumor tissue samples
Normal and tumor tissue array samples (Tissue Microarray FDA808ci, US Biomax, Rockville, MD, USA) were stained with the PD-L1 (SP263) rabbit monoclonal antibody using the final optimized protocol on the BenchMark ULTRA. A rabbit monoclonal negative-control Ig was also analyzed for the array staining run.
Evaluation of PD-L1 staining on tumor samples
All tumor sample evaluations were conducted by board-certified pathologists at Ventana’s College of American Pathologists accredited and Clinical Laboratory Improvement Act certified laboratory. Upon receipt of each sample, hematoxylin and eosin staining was performed to determine the number of tumor cells. The sample was considered acceptable for further analysis if it contained ≥100 viable tumor cells. The PD-L1 (SP263) assay was carried out on 4–6 μm sample sections mounted onto positively charged slides. PD-L1 staining was evaluated by estimating the percentage of cells stained at different intensities, from 0 to 3, with 0 representing no staining and 3 representing strong staining. This percentage was determined for staining localized in the cytoplasm and membrane of tumor cells. In addition, PD-L1 staining in tumor-associated immune cells (macrophages, dendritic cells, lymphocytes, etc.) was evaluated as a percentage of immune cells present in the tumor area.
PD-L1 scoring algorithm: Statistical analysis to identify the cut-off for determining PD-L1 positive/negative tumors
In NSCLC and HNSCC samples, PD-L1 was generally expressed as a continuum, ranging from a few tumor cells and/or immune cells expressing PD-L1 to the majority of tumor cells and immune cells expressing the target. Intensity of staining also varied, with mixtures of weak, moderate and intensely-stained tumor, and immune cells sometimes seen in single tumor specimens. To understand the association of the biomarker with clinical response, patient samples need to be classified into categories. For these purposes, samples were classified into two categories: high and low/no expression. The optimal scoring criteria were determined by Maximal Chi-square  and receiver operating characteristic (ROC) curves  of the PD-L1 staining parameters relative to clinical response in a subset of 155 patients with NSCLC enrolled in the NCT01693562 clinical trial [1, 34, 35]. The cut-off determination for the PD-L1 (SP263) assay was made following retrospective evaluation of their tumor samples as well as commercially available tumor samples. The considerations for the selected cut-off included prevalence, clinical outcome and the reproducibility of the test.
The endpoints used for the actual cut-off determination were the confirmed objective response (Y) per RECIST v1.1 based on investigator assessment and the percentage tumor cell membrane positivity for PD-L1 (X).
This scoring algorithm and the selected cut-off were utilized in the definitions of PD-L1 high and PD-L1 low/negative in the subsequent verification studies.
PD-L1 (SP263) assay verification studies
Cut-slide stability was evaluated on four tissue samples stained with the recommended assay protocol after storage under two different conditions (2–8 and 30 °C). Cut-slide stability was also assessed on slides stained at various timepoints after sectioning. Slides sectioned and stained at the Day 0 timepoint served as the comparator for the remainder of the tested timepoints (Day 3, 14, and monthly from Month 1–12 for NSCLC and Day 3, 14, and monthly from Month 1–10 for HNSCC).
Tissues were sectioned at various thicknesses (3–7 μm) to assess the effect of thickness on the staining performance of the PD-L1 (SP263) assay. The placenta tissue positive-control slides included in the staining run were sectioned at 4 μm. Slides were required to stain within 1.0 intensity point of each other and to maintain the same PD-L1 status (high or low/no expression).
Fixation type and time and ischemia
The effects of fixative type and fixation time were evaluated in tonsil-positive control tissue. Tonsil cases were processed in six fixatives (10 % neutral-buffered formalin [NBF], zinc formalin, 95 % alcohol, acidified formal alcohol (AFA), Z5 and Prefer) with multiple timepoints (1, 6, 12, 24, 72 h) in each fixative. The effects of ischemia were also investigated using KARPASS 299 xenograph tissues with ischemic times varying between 0, 0.5, 1, 2, 6, and 24 h. The immunostained slides were read and scored by a board-certified pathologist on a 0–3 intensity scale for specific PD-L1 staining and background. Data were then compared to the reference standard (10 % NBF for 24 h).
This design verification study was conducted to assess the PD-L1 (SP263) assay’s staining precision in NSCLC and HNSCC. Samples included both PD-L1 high and PD-L1 low/negative tissues across i) three different PD-L1 (SP263) antibody lots; ii) three OptiView DAB IHC Detection Kit lots; and iii) three BenchMark ULTRA instruments. This study was designed to verify the intermediate staining precision (inter-antibody lot, inter-detection kit lot, and intra-platform) of the PD-L1 (SP263) assay. A total of nine PD-L1 high and nine PD-L1 low/negative samples for each tumor type, spanning the range of PD-L1 expression, were used in the study.
Intra-day (slide to slide) precision
A total of 10 NSCLC and 10 HNSCC whole tissue samples (comprising five PD-L1 high and five PD-L1 low/negative samples for each tumor type) spanning the range of PD-L1 staining were evaluated across a cohort, which represented the dynamic range of PD-L1 expression. For intra-day repeatability, five replicate slides from each of the NSCLC or HNSCC specimens were stained on a single BenchMark ULTRA instrument (Tucson, AZ, USA) across two staining runs for NSCLC and HNSCC, respectively.
A total of 10 NSCLC and 10 HNSCC samples (comprising five PD-L1 high and five PD-L1 low/negative samples for each tumor type) spanning the range of PD-L1 expression were evaluated across three BenchMark ULTRA instruments. Three staining runs were conducted for NSCLC and HNSCC, respectively.
Inter-day (day-to-day) precision
A total of 10 NSCLC and 10 HNSCC whole tissue samples (comprising five PD-L1 high and five PD-L1 low/negative cases for each tumor type) spanning the range of PD-L1 expression were evaluated. Two replicate slides were stained for each sample on three BenchMark ULTRA instruments on five non-consecutive days over a minimum span of 20 days.
A total of 14 NSCLC and 14 HNSCC whole tissue samples (comprising seven PD-L1 high and seven PD-L1 low/negative cases for each tumor type) were evaluated. Cases were selected to cover the range of expression and included borderline cases around the cut-off. Each case was stained five different times in each laboratory. Three different laboratories were assessed. Two pathologists per laboratory conducted the scoring.
Reader verification of the scoring algorithm – inter- and intra-reader agreement
Between-reader (inter-reader) agreement with the PD-L1 (SP263) assay scoring algorithm was determined using a cohort of NSCLC tissue samples (previously screened for PD-L1 status) obtained from commercial sources and stained using the PD-L1 (SP263) assay. A total of 81 NSCLC samples (40 PD-L1 high and 41 PD-L1 low/negative) together with 100 HNSCC samples (50 PD-L1 high and 50 PD-L1 low/negative) were evaluated across the dynamic range of staining. Three readers were trained on the scoring algorithm and provided with the blinded and randomized study samples for scoring. Readers completed the initial scoring within 2 weeks and the scores were analyzed. There was a mandatory 2-week break period prior to the intra-reader precision scoring. Slides were then re-randomized and provided to the readers for intra-reader scoring.
Antibody sensitivity and specificity
The SP263 antibody showed a high degree of sensitivity and specificity for PD-L1 in cell lines with various levels of PD-L1 expression, as determined by flow cytometry, immunocytochemistry (Fig. 1), and Western blot analysis (Fig. 2). The IHC protocol demonstrated a wide dynamic range, as indicated by intensities of staining of cell lines appropriate to their varying levels of PD-L1 expression. As Fig. 1 illustrates, immunolabeling ranged from minimal or mild in HCT116 (very low expression, ~1,600 molecules per cell) and ACHN cells, to moderate in MDA-MB231 cells, to intense in LOX (high expression, ~15,000 receptors per cell).
Western blot analysis of cell lysates
A single band of the appropriate molecular weight of fully glycosylated PD-L1 (~55 kDa) was detected by Western blot in the H820, MDA-MB231, and H1975 cell lines using the PD-L1 (SP263) antibody (Fig. 2). No band was detected for the Calu-3 negative-control cells. These results demonstrated the high specificity of SP263 for PD-L1.
Additional cell lines were examined using immunocytochemistry to further evaluate the specificity and sensitivity of the PD-L1 (SP263) assay for the PD-L1 analyte. In cell lines with differential native PD-L1-specific expression, PD-L1 staining intensity with the IHC assay corresponded to the relative levels of PD-L1 expression (LOX > ~MDA-MB231 > ACHN > HCT116 > MCF-7) (Fig. 1 and Table 2). In addition, human embryonic kidney cells (HEK293) were transfected to express varying levels of PD-L1 and examined for PD-L1 reactivity. HEK cells containing empty vector showed no immunolabeling, whereas the transfected HEK cell lines displayed differential PD-L1-specific labeling appropriate to their protein expression levels. The HEK293 cells transfected to express the closely-related PD-L2 protein had no detectable immunostaining by the PD-L1 (SP263) assay (Table 2).
Staining of commercially available normal and tumor tissue arrays
The PD-L1 immunostaining features of SP263 were further examined in a panel of normal human tissues, where staining was notable particularly in lymph node, tonsil, stomach (typically chief, or zymogenic cells), and placenta. As tonsil and lymph node are known to contain immune cells expressing PD-L1, staining in these tissues was expected. Trophoblast-lineage cell staining in placenta was also anticipated. No specific PD-L1 staining was observed in the parenchyma of a single normal lung core.
The following tumor tissue samples stained using the SP263 assay demonstrated PD-L1 immunostaining of tumor cells: squamous cell carcinoma of the skin, infiltrating ductal carcinoma of the breast, cholangiocarcinoma of the liver, Hodgkin lymphoma, squamous cell carcinoma of the lung, gastric adenocarcinoma, diffuse large B-cell lymphoma (in stomach), squamous cell carcinoma of the uterine cervix, endometrial adenocarcinoma, and thyroid papillary carcinoma. Most specimens also demonstrated immunostaining of tumor-infiltrating immune cells. The degree of apparent background staining was reported as ≤0.5 (faint) intensity on all evaluated cores, a level that generally did not interfere with specific PD-L1 labeling and therefore was judged to be acceptable. Additional commercial samples of NSCLC and HNSCC tissue showed similar PD-L1 labeling in a number of tumors. Figure 3 illustrates the range of SP263 staining intensities and frequencies in these tumors.
PD-L1 scoring algorithm
Clinical response to durvalumab and PD-L1 expression in tumor biopsies correlated best with PD-L1 expression in tumor cells rather than immune cells. In a subset of 155 patients with NSCLC in the Phase 1/2 trial, the optimal cut-off identified statistically (Fig. 4) was 38 %. However, based on other considerations (e.g., prevalence in the population, ease of scoring by pathologists, optimizing for higher negative predictive value), a cut-off of 25 % of tumor cells with membrane staining for PD-L1 at any intensity level above background was selected for the verification studies. Logistic regression showed a significant relationship between tumor membrane staining score and probability of response (p-value = 0.0003, Fig. 5). Separate analysis of HNSCC samples from this study independently confirmed the reliability of the ≥25 % staining cut-off and exclusion of cytoplasmic tumor cell staining, immune cell staining, and staining intensity from the analysis of PD-L1 staining expression (data not shown).
PD-L1 (SP263) assay verification study results
The staining performance on NSCLC and HNSCC tissues stored at 2–8 and 30 °C passed the acceptance criteria. This test also demonstrated that staining at the Day 3 and 14, and Months 1–13 timepoints was consistent with results obtained on Day 0 for NSCLC tissues and staining at the Day 3 and 14, and Months 1–10 timepoints was consistent with results obtained on Day 0 for HNSCC tissues.
Tissue thickness and ischemia
Appropriate antibody staining was achieved across all tissue section thicknesses tested (3, 4, 5, 6, and 7 μm) (Table 3), which was consistent with PD-L1 high or low/negative outcomes for each case evaluated for both NSCLC and HNSCC. Variations in the types of tissue fixative used (either 10 % NBF, zinc formalin, or Z5) over time periods ranging from 6 to 72 h and cold tissue ischemia for periods ranging from 0 to 24 h also had a negligible effect on staining performance achieved with the PD-L1 (SP263) assay (Table 3). Fixation with 95 % alcohol, AFA and Prefer are not recommended for use with the assay as they caused a loss of staining intensity for PD-L1.
Intra-day (slide to slide) precision, intra-platform precision, and inter-day (day-to-day) precision
The intra-day reproducibility of the PD-L1 (SP263) assay within a single staining run exceeded the 90 % pass criterion set for this study; overall percentage agreement (OPA) for PD-L1 high vs. low/no expression was 100.0 % with a 95 % confidence interval (CI) of 92.9–100.0. The positive percentage agreement was 100.0 % (95 % CI: 88.6–100.0) and the negative percentage agreement was 100.0 % (95 % CI: 83.9–100.0). The assay also exceeded the 90 % pass criteria set for intra-platform precision (performance across three BenchMark ULTRA instruments) and inter-day precision (performance on the same BenchMark ULTRA instrument over 5 non-consecutive days for a minimum of 20 days) (Table 4). All the tissues tested in these assay performance studies had acceptable background staining, which did not interfere with interpretation of PD-L1 high vs. low/negative results. Inter-lot variability of either antibody or DAB visualization reagents also had a negligible effect on assay performance (Table 4).
Intermediate precision (inter-antibody lot, inter-detection kit lot, and intra-platform)
The intermediate precision design verification study was conducted to assess PD-L1 (SP263) assay staining precision on NSCLC tissues representing the clinical status range. The antibody exceeded the 90 % pass criteria set across the three antibody lots, three detection kit lots and three BenchMark ULTRA platforms (Table 4). All the tissues tested in these assay performance studies had acceptable background staining, which did not interfere with interpretation of PD-L1 high vs. low/negative results.
Intra-reader and inter-reader precision (agreement)
For NSCLC, the OPA between the three readers was 96.7 %. The average positive agreement (APA) and average negative agreement (ANA) between the three readers was 96.6 and 96.8 %, respectively (Table 5). The intra-reader (within reader) OPA was 96.3 %, the APA was 96.2 % and the ANA was 96.4 %. For HNSCC, the OPA between the three readers was 90.8 %. The APA and ANA between the three readers was 90.9 and 90.8 %, respectively. The intra-reader OPA was 94.3 %, the APA was 94.4 %, and the ANA was 94.3 %. These results met the requirement criteria for the assay.
For NSCLC, the average positive and average negative inter-laboratory reproducibility was 93.3 % and 79.5 %, respectively. The OPA was 86.4 %. For HNSCC, the average positive and average negative inter-laboratory reproducibility was 89.4 and 99.5 %, respectively. The OPA was 94.5 % (Table 6). These results met the requirement criteria for the assay.
IHC assays used to detect the presence of PD-L1 protein in tumor tissues are designed and needed to aid clinical treatment decisions by identifying cancer patients most likely to respond to antibody therapies that target the PD-1/PD-L1 pathway. This must be considered in the context that PD-L1 expression is complicated in a number of ways, as previously noted. Chief among these are that PD-L1 protein may localize to the cytoplasm or cell membrane, [19, 27] expression levels vary greatly among individual cells, [28, 29] and PD-L1 is expressed in tumor cells of a number of important cancer types as well as immune cells in even more cancers. In particular, PD-L1 expression is characteristic of a number of NSCLC [20, 38, 39] and HNSCC patients [18, 35, 40]. In this light, the VENTANA PD-L1 (SP263) Assay was developed to address many of these complexities and was validated to reliably detect PD-L1 protein in FFPE NSCLC and HNSCC tissue samples using a rabbit monoclonal antibody optimized for use with the OptiView DAB IHC Detection Kit.
The PD-L1 (SP263) assay showed the required level of analytical specificity and sensitivity for detecting engineered and endogenous PD-L1 protein in cell lines across a wide dynamic range of expression. Additionally, it was shown to detect PD-L1 expression levels as low as ~1,600 receptors per cell. The rabbit monoclonal antibody used in the assay was raised against the cytoplasmic region of human PD-L1 and produced a single clear band of the appropriate molecular weight in Western blot analysis. Target specificity was also demonstrated by transfecting PD-L1 into cell lines with no endogenous PD-L1 expression, producing clear staining with the PD-L1 (SP263) assay, and no staining in cells transfected with PD-L2. Antibodies raised against the cytoplasmic domain of PD-L1 have been reported to offer better visualization of membrane PD-L1 compared with those raised against the extracellular domain .
The assay detected PD-L1 immunoreactivity with the anticipated staining patterns in a panel of normal tissue samples with known PD-L1 expression (e.g., placental trophoblasts and immune cells) and in tumor cells from NSCLC and HNSCC tissue samples with a range of PD-L1 staining intensities and frequencies representing the heterogeneity of tissue expression. No unexpected cross-reactivity was observed with the antibody.
Numerous analytical variables have the potential to affect the reliability of assay results and the impact of these variables was extensively evaluated during assay development. In terms of preanalytical variables, the antibody demonstrated appropriate staining across all tissue section thicknesses tested and also accurately represented the PD-L1 high or PD-L1 low/negative staining status in each case. Changes in the recommended tissue fixative used (10 % NBF, zinc formalin, or Z5 [95 % alcohol, AFA, and Prefer not recommended]) over time periods ranging from 6 to 72 h and cold tissue ischemia for periods ranging from 0 to 24 h had a negligible effect on staining performance, as did cut-slide storage conditions of 2 − 8 and 30 °C for varying time periods of up to 12 months.
For assay performance over repeated measurements, the assay exceeded the 90 % pass criterion for intra-day reproducibility within a single staining run, inter-day precision (performance on the same BenchMark ULTRA instrument over 5 non-consecutive days for a minimum of 20 days) and intra-platform precision (performance across three BenchMark ULTRA instruments). The assay also exceeded the 90 % pass criteria for determination of intermediate precision across three antibody lots, three detection kit lots, and three BenchMark ULTRA platforms. Assay performance test scores (negative percentage agreement, positive percentage agreement, and OPA) were in the same range as those reported for the FDA-approved Dako PD-L1 IHC 28-8 pharmDx and PD-L1 IHC 22C3 pharmDx assays [14, 15]. Inter- and intra-reader performance scores (APA, ANA, and OPA) were all >90 % and comparable with observer-to-observer reproducibility values reported for the validated Dako PD-L1 IHC 28-8 pharmDx  and PD-L1 IHC 22C3 pharmDx assays .
A scoring algorithm for PD-L1 staining with the PD-L1 (SP263) assay was defined on the basis of an analysis of PD-L1 staining parameters observed from NSCLC and HNSCC samples from the NCT01693562 clinical trial of durvalumab, together with clinical response data. Statistical analysis of PD-L1 staining parameters in this study indicated that the parameter that correlated best with clinical response to durvalumab was PD-L1 expression in the membrane of tumor cells, regardless of staining intensity. Other PD-L1 parameters, however, remain under investigation. Samples were considered to have high expression when ≥25 % of viable tumor cells demonstrated membrane staining for PD-L1 at any intensity . The scoring algorithm thus separates patients into two groups: PD-L1 high (≥25 % of tumor cells with membrane staining for PD-L1), and PD-L1 low/negative (<25 % of tumor cells with membrane staining). Separate analysis of samples from NSCLC and HNSCC cohorts independently confirmed the reliability of the ≥25 % staining cut-off and exclusion of cytoplasmic tumor cell staining, immune cell staining, and staining intensity from the analysis of PD-L1 staining status. Using this defined scoring algorithm, the classifications of patient tumor samples as PD-L1 high or PD-L1 low/negative were highly reproducible among pathologists, with an OPA of 96.7 % for NSCLC among three pathologists.
Although several different assays to determine PD-L1 positivity in tumor tissue have been developed, few have been performance tested using comparable assay conditions. There may be differences in assay performance owing to the diversity of antibody clones with different affinities, raised against different areas (epitopes) on the PD-L1 molecule (e.g., clones E1L3N, SP142, and SP263 are raised to epitopes within the intracellular domain, and clones 22C3 and 28-8 to epitopes within the extracellular domain). Furthermore, a number of associated IHC protocols have been developed, relying on differing antigen retrieval conditions and staining platforms in particular. These differences are likely to generate different staining patterns [22, 28, 55]. Tissue fixation, handling, processing, and timing of sample collection in relation to current disease and treatment stage may also influence assay outcomes. For these and other reasons, the reliability of some data reported on PD-L1 expression has been difficult to assess, and highlights the need for standardized use of well-validated PD-L1 assays for the detection and scoring of PD-L1 in patient tumor samples. A recent comparative study featuring the VENTANA PD-L1 (SP263) Assay, showed a high analytical correlation between the three different commercially available PD-L1 assays (Dako 28.8, Dako 22C3 and VENTANA SP263) .
The heterogeneity of PD-L1 expression also poses a challenge for pathologists [28, 29]. Unlike other biomarkers in NSCLC, PD-L1 protein expression does not give a binary signal, instead, it presents as a continuum of expression including absent, low, medium, and high levels, and also varies between tumor cells ; some tumors classified as PD-L1 low/negative at the biopsy site may be PD-L1 high at a different location. The creation of a binary positive or negative result for PD-L1 status is achieved using a staining cut-off. This can mean that the probability of response to anti-PD-1/PD-L1 treatment differs very little in patients with PD-L1 low/negative tumors just below the cut-off, and patients with PD-L1 high tumors just above the cut-off. The lower the staining cut-off, the greater the risk of misclassifying patients in terms of probability of response . These and other concerns are currently being evaluated in ongoing clinical trials with durvalumab monotherapy and combination therapies.
This analysis demonstrated the reliability of the PD-L1 (SP263) assay to determine the PD-L1 expression of NSCLC and HNSCC tumor samples obtained in a clinical setting based on a ≥25 % cut-off value for positively stained tumor cells. Preliminary data from retrospective analyses of tumor samples obtained from a clinical trial of the anti-PD-L1 agent durvalumab, demonstrated that PD-L1 high expression, identified by the PD-L1 (SP263) assay and scoring algorithm, was a useful predictor of treatment response .
The VENTANA PD-L1 (SP263) Assay met all of the predefined acceptance criteria (according to its proposed intended use as a clinical diagnostic test), showing analytical specificity, sensitivity, robustness and precision, and obtaining the required performance scores for day-to-day, site-to site and observer-to-observer repeatability and reproducibility, confirming its reliability for staining of FFPE NSCLC and HNSCC samples across different testing environments.
The PD-L1 (SP263) assay is currently in use in ongoing clinical trials of durvalumab, as monotherapy and in combination with tremelimumab, as part of a comprehensive clinical development program in NSCLC and HNSCC. These studies support the use of the PD-L1 (SP263) assay for testing on clinical samples and form the basis for confirming clinical utility.
Acidified formal alcohol
Average negative agreement
Average positive agreement
Area under the curve
Flow cytometry analysis
Food and Drug Administration
Head and neck squamous cell carcinoma
Horse radish peroxidase
Negative percentage agreement
non-small cell lung cancer
Overall percentage agreement
Objective response rate
Programmed cell death-1
Programmed cell death ligand-1
Programmed cell death ligand-2
Positive percentage agreement
Response Evaluation Criteria In Solid Tumors
Receiver operating characteristic
Rebelatto M, Mistry A, Sabalos C, Walker J, Midha A, Steele K, et al. Development of a PD-L1 Companion Diagnostic Assay for Treatment With MEDI4736 in NSCLC and SCCHN Patients. Chicago: Poster presented at the 51st American Society of Clinical Oncology Annual Meeting; 2015. Abstract 8033.
Rebelatto MC, Mistry A, Sabalos C, Schechter N, Walker J, Midha A, et al. An immunohistochemical PD-L1 companion diagnostic assay for treatment with durvalumab (MEDI4736) in NSCLC patients. Cancer Immunol Res. 2016;4(1 Suppl):B005. abstr.
Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer. 2008;112(12):2710–9. doi:10.1002/cncr.23442.
Shin DM, Khuri FR. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck. 2013;35(3):443–53. doi:10.1002/hed.21910.
D’Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(5_Suppl):v116–9. doi:10.1093/annonc/mdq189.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. doi:10.1038/nrc3239.
Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–82. doi:10.1200/JCO.2014.59.4358.
Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy. 2013;5(3):215–29. doi:10.2217/imt.13.9.
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–77. doi:10.1038/nri2326.
Food and Drug Administration (FDA). News Release. FDA approves Opdivo to treat advanced form of kidney cancer. 23 November 2015. Last updated 25 November 2015. Last accessed 17 March 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm.
European Medicines Agency (EMA). What is Opdivo and what is it used for? Updated 4 March 2016. Last accessed 17 March 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001876.jsp&mid=WC0b01ac058001d124.
Merck Sharp & Dohme. Highlights of prescribing information: Keytruda. Updated December 2015. Last accessed 11 August 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s004s006lbl.pdf.
European Medicines Agency (EMA). What is Keytruda and what is it used for. Updated 30 July 2015. Last accessed 16 March 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp&mid=WC0b01ac058001d124.
Food and Drug Administration (FDA). Summary of safety and effectiveness data (SSED). PD-L1 IHC 28–8 pharmDx. 9 October 2015. Last accessed 11 January 2016. http://www.accessdata.fda.gov/cdrh_docs/pdf15/p150025b.pdf.
Food and Drug Administration (FDA). Summary of safety and effectiveness data (SSED). PD-L1 IHC 22C3 pharmDx. 2 October 2015. Last accessed 11 January 2016. http://www.accessdata.fda.gov/cdrh_docs/pdf15/p150013b.pdf.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331.
Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170(3):1257–66. doi:10.4049/jimmunol.170.3.1257.
Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733–41. doi:10.1158/0008-5472.CAN-12-2384.
Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26(4):812–7. doi:10.1093/annonc/mdv009.
Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015;89(2):181–8. doi:10.1016/j.lungcan.2015.05.007.
Kim HS, Lee JY, Lim SH, Park K, Sun JM, Ko YH, et al. Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma. Cancer Res Treat. 2016;48(2):527–36. doi:10.4143/crt.2015.249.
Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, et al. PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol Res. 2015;3(12):1308–15. doi:10.1158/2326-6066.CIR-15-0116.
Jørgensen JT. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. Expert Rev Mol Diagn. 2016;16(2):131–3. doi:10.1586/14737159.2016.1117389.
Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol. 2015;10(7):985–9. doi:10.1097/JTO.0000000000000526.
He XH, Xu LH, Liu Y. Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain. Acta Pharmacol Sin. 2005;26(4):462–8. doi:10.1111/j.1745-7254.2005.00086.
Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol. 2005;235(2):109–16. doi:10.1016/j.cellimm.2005.07.007.
Yu GT, Bu LL, Huang CF, Zhang WF, Chen WJ, Gutkind JS, et al. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma. Oncotarget. 2015;6(39):42067–80. doi:10.18632/oncotarget.5955.
Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468(5):511–25. doi:10.1007/s00428-016-1910-4.
Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. doi:10.1016/S0140-6736(15)01281-7.
Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052–62. doi:10.1158/2326-6066.cir-14-0191.
Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 2010;3(1):81–91. doi:10.1038/mi.2009.112.
Matsumoto K, Fukuyama S, Eguchi-Tsuda M, Nakano T, Matsumoto T, Matsumura M, et al. B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem Biophys Res Commun. 2008;365(1):170–5. doi:10.1016/j.bbrc.2007.10.156.
Matsumoto K, Inoue H, Nakano T, Tsuda M, Yoshiura Y, Fukuyama S, et al. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J Immunol. 2004;172(4):2530–41. doi:10.4049/jimmunol.172.4.2530.
Rizvi NA, Brahmer JR, Ou S-HI, Segal NH, Khleif S, Hwu W-J, et al. Safety and Clinical Activity of MEDI4736, an Anti-Programmed Cell Death-Ligand 1 (PD-L1) Antibody, in Patients With non-Small Cell Lung Cancer (NSCLC). Chicago: Poster presented at the 51st American Society of Clinical Oncology Annual Meeting; 2015. Abstract 8032.
Segal NH, Ou S-HI, Balmanoukian AS, Fury MG, Massarelli E, Brahmer JR, et al. Safety and Efficacy of MEDI4736, an Anti-PD-L1 Antibody, in Patients from a Squamous Cell Carcinoma of the Head and Neck (SCCHN) Expansion Cohort. Chicago: Poster presented at the 51st American Society of Clinical Oncology Annual Meeting; 2015. Abstract 3011.
Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer. 2014;50(7):1361–9. doi:10.1016/j.ejca.2014.01.018.
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94(1):107–16. doi:10.1038/labinvest.2013.130.
Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer. 2013;14(2):157–63. doi:10.1016/j.cllc.2012.05.006.
Schmidt LH, Kummel A, Gorlich D, Mohr M, Bröckling S, Mikesch JH, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One. 2015;10(8), e0136023. doi:10.1371/journal.pone.0136023.
Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63(19):6501–5.
Antonia SJ, Gettinger S, Goldman LQ, Chow R, Juergens H, Borghaei H, et al. Safety and efficacy of first-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in non-small cell lung cancer (NSCLC): metastatic non-small cell lung cancer. Int J Rad Oncol. 2014;90(5_Suppl):S32–3. Abstract 168.
Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10(6):e0130142. doi:10.1371/journal.pone.0130142.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. doi:10.1056/NEJMoa1501824.
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12. doi:10.1200/jco.2014.58.3708.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7. doi:10.1038/nature14011.
Rizvi NA, Garon EB, Patnaik A, Gandhi L, Leighl NB, Balmanoukian AS, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15_Suppl):8007. abstr.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–65. doi:10.1016/S1470-2045(15)70054–9.
Rizvi NA, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQ, Goldman J, et al. First-line monotherapy with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status. Int J Rad Oncol. 2014;90(5Suppl):S31. Abstract 165.
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46. doi:10.1016/S0140-6736(16)00587–0.
Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJ, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: a phase Ib trial. Eur J Cancer. 2015;51(3 Suppl):S629. Abstract 3090.
Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scott M, Scorer P, et al. A Comparative Study of PD-L1 Diagnostic Assays and the Classification of Patients as PD-L1 Positive and PD-L1 Negative. New Orleans: Poster presented at the American Association for Cancer Research (AACR) Annual Meeting; 2016. Abstract LB-094.
Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny Jr J, Taylor C, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015;23(8):541–9. doi:10.1097/pai.0000000000000256.
Miller R, Siegmund D. Maximally selected chi square statistics. Biometrics. 1982;38:1001–16.
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5.
Kerr KM, Hirsch FR. Programmed death ligand 1 immunohistochemistry: friend or foe? Arch Pathol Lab Med. 2016;140(4):326–31. doi:10.5858/arpa.2015-0522-SA.
Medical writing and editorial assistance were provided by Isobel Lever, PhD, of CircleScience (Ashfield Healthcare, Macclesfield, UK) (funded by MedImmune). Flow cytometry analyses of cell lines were done by Stacy Fuhrmann (MedImmune LLC). The MedImmune pathology group, especially Charles Brown II (MedImmune LLC) and Anmarie Boutrin (MedImmune LLC), had great involvement in development of PD-L1 assays and handling of clinical samples for this study. Kellie Hazell (Ventana Medical Systems Inc. [Roche]) was the Clinical Sciences Project Manager for Ventana’s CAP/CLIA laboratory where all the clinical trial samples were tested. Alma Nielsen, Greg Martin, and Xiaoling Xia (all of Ventana Medical Systems Inc. [Roche]), were instrumental in the assay design and optimization. Laura Richman (MedImmune LLC) was instrumental in decisions to select the SP263 clone for the assay.
Availability of data and materials
Presented in the main paper.
This study was sponsored by MedImmune. The sponsor contributed to the design and implementation of the study, collection, analysis and interpretation of data, and writing of the report. The authors had final responsibility for the decision to submit for publication.
All authors were involved in study design, data interpretation and critical revision of the manuscript. Data acquisition, including experimental planning and results analysis was carried out by MCR, AM, AMis, CS, NS, KES, PBR, JABH, XL, XJ and JW. All authors reviewed and approved the final manuscript draft.
MCR, KES, XL and XJ are employees of MedImmune LLC. PBR and JABH are employees of Pfizer and former employees of MedImmune LLC. AM is a former employee of AstraZeneca. JW is an employee of AstraZeneca. AMis, CS, and NS are employees of Ventana Medical Systems Inc. (Roche).
MCR, XL, and XJ are employees of MedImmune LLC and hold stocks or shares in AstraZeneca. AM is a former employee of AstraZeneca. JW is an employee of AstraZeneca and holds stocks or shares in AstraZeneca. AMis is an employee of Ventana Medical Systems Inc. (Roche) and owns stocks or shares; has received fees for travel, accommodations or expenses. AMis’s institute has received fees for research funding from MedImmune LLC. CS is an employee of Ventana Medical Systems Inc (Roche) and holds stocks or shares in HTG Molecular Diagnostics. NS is an employee of Ventana Medical Systems Inc (Roche). KES is an employee of MedImmune LLC. KES and his spouse hold stocks or shares in AstraZeneca. KES holds patents, royalties and other intellectual properties from MedImmune LLC. PBR is an employee of Pfizer and former employee of MedImmune LLC and owns stocks or shares in Pfizer and AstraZeneca. JABH is an employee of Pfizer and a former employee of MedImmune LLC.
Consent for publication
Not applicable; no individual person’s data presented.
Ethics approval and consent to participate
For the Phase 1/2 durvalumab trial (NCT01693562), the study protocol was reviewed and approved by the Institutional Review Board of the participating centers and informed consent was obtained from all patients.
All animal work was conducted in a United States Department of Agriculture certified facility and approved by its Institutional Animal Care and Use Committee.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Rebelatto, M.C., Midha, A., Mistry, A. et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol 11, 95 (2016). https://doi.org/10.1186/s13000-016-0545-8